0.0005USD0.00%Mkt Cap: 2352 USDP/E: —Last update: 2026-05-25
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.35K USD
Enterprise Value-5.13M USD
Revenue (TTM)—
Gross Profit-21.62M USD
Net Income (TTM)-35.81M USD
Revenue/Share—
Last Price0.0005 USD
Fiscal Year EndDec 2023
MR QuarterMar 2024
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.16
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)-12.57
EPS (Forward)-2.25
52W Range
0.00023% of range0.0100
52W High0.0100 USD
52W Low0.0002 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE617.96%
ROA-174.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.55M USD
CapEx (TTM)97.00K USD
FCF Margin—
FCF Yield-751100.17%
Net Debt-5.13M USD
Net Debt/EBITDA0.16
Balance Sheet
Debt/Equity-3.55
Current Ratio1.03
Quick Ratio0.99
Book Value/Sh0.2120 USD
Cash/Share5.396 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJan 12, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.70M
Float4.67M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio1.0d
Short % Float1.97%
Short % Out.1.95%
Shares Short91.62K
Short (prev mo.)110.66K
Technical
SMA 500.0003 (+81.2%)
SMA 2000.0003 (+99.6%)
Beta2.42
S&P 52W Chg28.31%
Avg Vol (30d)2.83K
Avg Vol (10d)7.04K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—